Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

hospira, inc. - magnesium sulfate heptahydrate (unii: sk47b8698t) (magnesium cation - unii:t6v3lhy838) - magnesium sulfate heptahydrate 500 mg in 1 ml - magnesium sulfate injection, usp is suitable for replacement therapy in magnesium deficiency, especially in acute hypomagnesemia accompanied by signs of tetany similar to those observed in hypocalcemia. in such cases, the serum magnesium (mg++ ) level is usually below the lower limit of normal (1.5 to 2.5 meq/liter) and the serum calcium (ca++ ) level is normal (4.3 to 5.3 meq/liter) or elevated. in total parenteral nutrition (tpn), magnesium sulfate may be added to the nutrient admixture to correct or prevent hypomagnesemia which can arise during the course of therapy. magnesium sulfate injection, usp is also indicated for the prevention and control of seizures (convulsions) in pre-eclampsia and eclampsia, respectively. parenteral administration of the drug is contraindicated in patients with heart block or myocardial damage.

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

hospira, inc. - magnesium sulfate heptahydrate (unii: sk47b8698t) (magnesium cation - unii:t6v3lhy838) - magnesium sulfate heptahydrate 10 mg in 1 ml - magnesium sulfate in 5% dextrose injection is indicated for: magnesium sulfate in 5% dextrose injection is contraindicated in patients: risk summary magnesium sulfate in 5% dextrose injection is indicated in pregnant women for the prevention of eclampsia in women with preeclampsia and the treatment of seizures and prevention of recurrent seizures in women with eclampsia. fetal, neonatal, and maternal risks are discussed throughout the labeling. clinical considerations labor or delivery: magnesium sulfate in 5% dextrose injection is not approved for the treatment of pre-term labor. administration of magnesium sulfate in 5% dextrose injection to pregnant women longer than 5 to 7 days may lead to hypocalcemia and bone abnormalities in the developing fetus, including skeletal demineralization and osteopenia [see warnings and precautions (5.1)] . the use of intravenous magnesium in pregnant women increases human milk magnesium concentrations only slightly and oral absorption of magnesium by the infant is poor. the

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

santarus, inc. - omeprazole (unii: kg60484qx9) (omeprazole - unii:kg60484qx9), sodium bicarbonate (unii: 8mdf5v39qo) (sodium bicarbonate - unii:8mdf5v39qo), magnesium hydroxide (unii: nbz3qy004s) (magnesium hydroxide - unii:nbz3qy004s) - tablet, chewable - 20 mg - zegerid with magnesium hydroxide is indicated for short-term treatment of active duodenal ulcer. most patients heal within four weeks. some patients may require an additional four weeks of therapy. zegerid with magnesium hydroxide is indicated for short-term treatment (4-8 weeks) of active benign gastric ulcer. (see clinical pharmacology, clinical studies, gastric ulcer.) zegerid with magnesium hydroxide is indicated for the treatment of heartburn and other symptoms associated with gerd. zegerid with magnesium hydroxide is indicated for the short-term treatment (4-8 weeks) of erosive esophagitis which has been diagnosed by endoscopy. (see clinical pharmacology, clinical studies.) the efficacy of zegerid with magnesium hydroxide used for longer than 8 weeks in these patients has not been established. in the rare instance of a patient not responding to 8 weeks of treatment, it may be helpful to give up to an additional 4 weeks of treatment. if there is recurrence of erosive esophagitis or gerd symptoms (eg, hea

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

cardinal health - magnesium citrate (unii: rho26o1t9v) (magnesium cation - unii:t6v3lhy838) - magnesium citrate 1.745 g in 29.6 mg - saline laxative for relief of occasional constipation (irregularity).  generally produces bowel movement in 1/2 to 6 hours - kidney disease - a magnesium or potassium-restricted diet - abdominal pain or nausea or vomiting - noticed a sudden change in bowel habits that persists over a period of 2 weeks - already used a laxative for a period longer than 1 week you have rectal bleeding or failure to have a bowel movement after use.  these could be signs of a serious condition.

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

unfi - magnesium citrate (unii: rho26o1t9v) (magnesium cation - unii:t6v3lhy838) - magnesium citrate 1.745 g in 29.61 ml - saline laxative for relief of occasional constipation (irregularity). generally produces bowel movement in 1/2 to 6 hours. - kidney disease - a magnesium-restricted diet - abdominal pain, nausea or vomiting - noticed a sudden change in bowel habits that persists over a period of 2 weeks - already used a laxative for a period longer than 1 week are taking any other drug. take this product 2 or more hours before or after other drugs. laxatives may affect how other drugs work. you have rectal bleeding or failure to have a bowel movement after use. these could be signs of a serious condition.

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

better living brands llc - magnesium citrate (unii: rho26o1t9v) (magnesium cation - unii:t6v3lhy838) - magnesium citrate 1.745 g in 29.6 ml - saline laxative for relief of occasional constipation (irregularity). generally produces bowel movement in 1/2 to 6 hours - kidney disease - a magnesium or potassium-restricted diet - abdominal pain, nausea, or vomiting - noticed a sudden change in bowel habits that persists over a period of 2 weeks - already used a laxative for a period longer than 1 week taking any other drug.  take this product 2 or more hours before or after other drugs.  laxatives may affect how other drugs work. you have rectal bleeding or failure to have a bowel movement after use. these could be signs of a serious condition.

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

target corp - magnesium citrate (unii: rho26o1t9v) (magnesium cation - unii:t6v3lhy838) - magnesium citrate 1.745 g in 29.61 ml - saline laxative for relief of occasional constipation (irregularity). generally produces bowel movement in 1/2 to 6 hours. - kidney disease - a magnesium-restricted diet - abdominal pain, nausea or vomiting - noticed a sudden change in bowel habits that persists over a period of 2 weeks - already used a laxative for a period longer than 1 week are taking any other drug. take this product 2 or more hours before or after other drugs. laxatives may affect how other drugs work. you have rectal bleeding or failure to have a bowel movement after use. these could be signs of a serious condition.

Ιρλανδία - Αγγλικά - HPRA (Health Products Regulatory Authority)

johnson & johnson (ireland) limited - famotidine; magnesium hydroxide; calcium carbonate - chewable tablet - 10/165/800 milligram(s) - h2-receptor antagonists; famotidine, combinations

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

mylan institutional llc - magnesium sulfate heptahydrate (unii: sk47b8698t) (magnesium cation - unii:t6v3lhy838) - magnesium sulfate in 5% dextrose injection is indicated for: magnesium sulfate in 5% dextrose injection is contraindicated in patients: risk summary magnesium sulfate in 5% dextrose injection is indicated in pregnant women for the prevention of eclampsia in women with preeclampsia and the treatment of seizures and prevention of recurrent seizures in women with eclampsia. fetal, neonatal, and maternal risks are discussed throughout the labeling. clinical considerations labor or delivery: magnesium sulfate in 5% dextrose injection is not approved for the treatment of pre-term labor. administration of magnesium sulfate in 5% dextrose injection to pregnant women longer than 5 to 7 days may lead to hypocalcemia and bone abnormalities in the developing fetus, including skeletal demineralization and osteopenia [see warnings and precautions (5.1)] . the use of intravenous magnesium in pregnant women increases human milk magnesium concentrations only slightly and oral absorption of magnesium by the infant is poor. th

Ιρλανδία - Αγγλικά - HPRA (Health Products Regulatory Authority)

jntl consumer health i (ireland) limited - famotidine; magnesium hydroxide; calcium carbonate - chewable tablet - h2-receptor antagonists; famotidine, combinations